Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585999 · ClinicalTrials.gov registry record · NA
The Pharmacokinetics of 12 Week Continuous Patch Use
A NA study, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02585999: Completed NA study, sponsored by Boston Medical Center.
NCT02585999 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02585999, a NA study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The primary objective is to assess the change in serum ethinyl estradiol (EE2) levels over 12 weeks of continuous contraceptive patch use. The secondary objective is assessing the the norelgestromin (NGMN) levels over the 12 weeks of continuous contraceptive patch use.
Primary Outcome
Liquid chromatography-tandem triple quadrupole mass spectrometry was utilized to assess EE2
Interventions
- DEVICE Xulane Contraceptive Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-06 |
| Phase | NA |
What the finished NCT02585999 record still lists
NCT02585999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Xulane Contraceptive Patch is the first listed.
NCT02585999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02585999 about?
NCT02585999 is a clinical study titled "The Pharmacokinetics of 12 Week Continuous Patch Use". Investigators propose a descriptive pharmacokinetic study of the serum hormone levels of estrogen and progesterone with extended use (12 weeks) of the contraceptive patch. The primary objective is to assess the change in serum ethinyl estradiol (EE2) levels over 12 weeks of continuous contraceptive ...
What is the current status of trial NCT02585999?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02585999?
The interventions under investigation include: Xulane Contraceptive Patch (DEVICE).
Who is sponsoring clinical trial NCT02585999?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02585999's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia